

Cell Selection and Separation System
细胞分选与分离系统
- SKU CPR-0003
- Cell Processing
- CE (to be confirmed)
- ISO 13485 manufacturing (to be confirmed)
- IEC 61010-1 compliance (to be confirmed)
Price on request — FOB / CIF quoted per order
Prices depend on configuration, quantity and destination port.
Key specifications
| Selection principle | Immunomagnetic or density gradient |
|---|---|
| Purity | Typically 90–99% for validated markers |
| Recovery | 50–90% depending on method |
| Sample input | Up to 10^10 cells per run |
| Processing time | 30 min–3 h |
| Fluid path | Closed, single-use |
By Lab Manufacturers China Technical TeamLast reviewed Standards: EU GMP Annex 1, EU GMP Annex 11, 21 CFR Part 11
What is the Cell Selection and Separation System?
A cell selection and separation system enriches a target cell population from apheresis material or culture using immunomagnetic beads or density gradients. It delivers a defined, high-purity starting population for downstream expansion.
What is the Cell Selection and Separation System?
A cell selection and separation system enriches a target cell population from apheresis material or culture using immunomagnetic beads or density gradients. It delivers a defined, high-purity starting population for downstream expansion.
Overview
A cell selection and separation system isolates the cells that will be expanded or administered. Immunomagnetic methods label target cells with antibody-coated magnetic particles and pass the suspension through a magnetized column, retaining the target while unlabeled cells flow through; positive selection captures the target, and negative selection depletes unwanted cells. Beads may be removed after selection, or left when they are degradable and clinically acceptable. Density-gradient separation, often automated, layers the sample over a medium so that cells band by density and can be collected. Some platforms add fluorescence-activated or microfluidic sorting for higher purity or rare populations. Key performance criteria are purity, recovery, viability and throughput, and the system should be closed and single-use where the product is therapeutic.
How does it work?
Cell processing equipment manipulates living cells while preserving viability and function. Separation and selection use immunomagnetic beads or density gradients to enrich a target population. Activation with antibodies or cytokines prepares T cells or other lymphocytes for expansion, which is then carried out in closed, gas-permeable culture systems with controlled temperature, dissolved oxygen and feeding. Washing and concentration use centrifugation in a closed chamber or tangential flow filtration to remove medium, beads and impurities and to reach a defined dose volume. Formulation adds a cryoprotectant such as dimethyl sulfoxide before controlled-rate freezing stores the product at low temperature. Because the product is living and often autologous, the equipment is designed for closed processing, single-use fluid paths, low shear and full traceability of each patient batch.
What are the key features?
- Immunomagnetic positive or negative selection
- Automated density-gradient separation option
- Closed single-use tubing sets
- Bead removal step where required
- Purity, recovery and viability monitoring
What are the technical specifications?
A typical cell selection and separation system configuration offers selection principle of Immunomagnetic or density gradient, purity of Typically 90–99% for validated markers, recovery of 50–90% depending on method, sample input of Up to 10^10 cells per run, processing time of 30 min–3 h and fluid path of Closed, single-use. Values are indicative of the product class; the exact figures for each configuration are confirmed on the quotation and the calibration documents supplied with the instrument.
Which applications is it used for?
The Cell Selection and Separation System is used in T cell enrichment for therapy, stem cell selection, depletion of unwanted cell populations and isolation of rare cell populations. Across the wider Cell Processing class, laboratories also deploy it for autologous cell therapy manufacturing, allogeneic cell product manufacturing and CAR-T and TCR cell production.
Which standards and certifications apply?
Relevant standards and methods include EU GMP Annex 1, EU GMP Annex 11, 21 CFR Part 11, 21 CFR Part 1271, ISO 13485, USP <1046> and IEC 61010-1. Certification candidates for this model are CE, ISO 13485 manufacturing and IEC 61010-1 compliance; each is to be confirmed for the specific configuration before shipment, and certificates are supplied only where they have been issued.
Handle all materials under the appropriate biosafety and cleanroom conditions, and use aseptic technique throughout. Verify that reagents and consumables are qualified for the process and that lot changes are controlled. Confirm closed-system integrity, especially connectors and welds, and monitor cell counts, viability and sterility at defined points. Programmable steps should be locked and version controlled, and each patient or batch record should capture operator, reagents and deviations. Maintain temperature control and check that shear and centrifugation settings do not reduce viability. For regulated production, validate the process, qualify the equipment and confirm that software meets data integrity requirements. Electrical safety follows IEC 61010-1.
How do I select the right Cell Selection and Separation System?
Choose a selection system from the required purity, recovery and target frequency. In an RFQ specify selection principle, purity and recovery targets, sample input range, processing time, whether bead removal is needed and the closedness and traceability requirements.
How does it compare with other Cell Processing variants?
Select equipment from the cell type, the target dose and the closedness your product requires. Autologous therapies need single-use, closed fluid paths that avoid open manipulation, so specify bag and connector formats and whether processing is manual, semi-automated or fully automated. For selection, choose immunomagnetic or density-based methods according to the required purity, recovery and whether the target is rare. For expansion, match the culture surface area, gas exchange and feeding strategy to the expected fold expansion and cell density. For washing and concentration, define the final dose volume, acceptable recovery and whether a cryoprotectant must be added in the same closed circuit. Confirm traceability, batch records and validation support, and check that the system fits your cleanroom grade and operator workflow.
Full specifications
| Selection principle | Immunomagnetic or density gradient |
|---|---|
| Purity | Typically 90–99% for validated markers |
| Recovery | 50–90% depending on method |
| Sample input | Up to 10^10 cells per run |
| Processing time | 30 min–3 h |
| Fluid path | Closed, single-use |
| Bead removal | Optional in-line step |
| Control | Automated with program and record |
Indicative values for this product class. Final specifications are confirmed on the quotation and in the calibration documents supplied with the instrument.
Applications
- T cell enrichment for therapy
- Stem cell selection
- Depletion of unwanted cell populations
- Isolation of rare cell populations
Key features
- Immunomagnetic positive or negative selection
- Automated density-gradient separation option
- Closed single-use tubing sets
- Bead removal step where required
- Purity, recovery and viability monitoring
Frequently asked questions about Cell Selection and Separation System
Positive selection captures the target cells directly on antibody-coated magnetic particles. Negative selection removes unwanted cells and leaves the target untouched, which can better preserve cell function but generally gives lower purity than positive selection.
It depends on the bead type and product. Some beads must be removed with a release step before administration, while degradable beads may remain if they are shown to be clinically acceptable. The choice is defined by the product specification and regulatory expectations.
A sample of the product is stained with marker-specific antibodies and analyzed by flow cytometry to report the percentage of target cells, together with recovery and viability. These results are part of the batch release data for the cell product.
It manufactures cell-based products by selecting, activating, expanding, washing, concentrating, formulating and freezing cells. It is used in cell therapy production, stem cell processing and regenerative medicine, where closed, documented handling preserves viability and meets quality requirements.
Cell therapy products are living and often autologous, so open handling risks contamination and mix-ups between patients. Closed processing with single-use bags and aseptic connectors keeps the product isolated from the environment and from other batches, which is central to both safety and traceability.
Targets depend on the product and route of administration, but cell therapies commonly require high post-thaw viability, often above 70 to 80 percent, and defined recovery of the target population. Shear, temperature excursions, cryoprotectant exposure and hold times all affect these values.
Related models






